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Dear Editor,
Head and neck cancer is an important cause of ill health with
rapidly changing aetiology and approaches to treatment.1,2
Survival appears to have improved, but the reasons for this
are unclear.3 There is no large population-based compre-
hensive longitudinal biomedical resource of peoplewithhead
and neck cancer. Several registries exist, such as the US
National Cancer Institute surveillance epidemiology and end
results programme, but these lack individual consent and
biological samples.4 Large retrospective aetiological case–
control studies with consent, clinical and socio-demographic
information and biological samples, such as the International
Head and Neck Cancer Epidemiology Consortium, have
limited follow-up data, focus on past rather than current
exposures and recruited people at different stages of treat-
ment.5 Existing prospective studies have fewer than 1000
participants and are often based on follow-up of randomised
trials (a potentially unrepresentative group).6
The importance of adequately powered, population-
based, comprehensive, longitudinal biomedical resources
in healthy populations is accepted. The value of similar
biomedical resources for clinical conditions is increasingly
appreciated. We report here on recruitment, response rates
and characteristics of 5511 people enrolled in a prospective
clinical cohort study: head and neck 5000.7
Methods
Ethical considerations
The study was approved by the National Research Ethics
Committee (South West Frenchay Ethics Committee,
reference 10/H0107/57, 5th November 2010) and approved
by the research and development departments for partici-
pating NHS Trusts.
Recruitment to the study
We have described the study methods in detail previously.7
Briefly, all people with a new diagnosis of head and neck
cancer were eligible. People were recruited before their
treatment started, unless their treatment was their diagnostic
procedure. Participants offered palliative support were
recruited as soon after diagnosis as possible. A research
nurse obtained a wide-ranging consent. The teams kept logs
of the number of eligible people who were approached and
the reason they were not recruited.
Baseline data and sample collection
The research nurse gave participants three questionnaires.
The first enquired about social and economic circumstances,
overall health and lifestyle behaviours. The second enquired
about physical and psychological health, well-being and
quality of life. The third enquired about past sexual
behaviours.7 The nurse abstracted information from the
hospital medical records about diagnosis, treatment and
Correspondence: A.R. Ness NIHR Biomedical Research Unit in Nutrition,
Diet and Lifestyle, Level 3, University Hospitals Bristol Education Centre,
Upper Maudlin Street, Bristol BS2 8AE, UK. Tel.: 0117 342 1751; Fax 0117
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comorbidity onto a data capture form and asked participants
to provide a blood sample and a saliva sample. The nurse
posted the samples to the study laboratory. We asked local
pathologists to send paraffin embedded tumour blocks along
with an anonymised copy of the participant’s histopathology
report.7
Study follow-up
We have not collected any further biological samples. We
sent out follow-up questionnaires at 4 and 12 months after
the person joined the study. We added questions about fear
of recurrence in the 4- and 12-month questionnaires. A
separate questionnaire asking about late radio-toxicity was
sent to people at 12 months who had a course of radiother-
apy as part of their initial treatment plan. The research nurses
abstracted updated clinical information from the hospital
medical records at 4 and 12 months. We have flagged
participantswith theUKHealth and Social Care Information
Centre to obtain data on date and cause of death.
Statistical analysis
Agewas calculated from the date on the consent form and the
date of birth on the data capture form.Gender, diagnosis and
stage were recorded on the data capture form. We coded
diagnosis using the International Classification of Diseases
(ICD) version 10.8 We derived the clinical staging of the
tumour from T (characteristics of the tumour site), N
(degree of lymph node involvement) and M (the absence or
presence of metastases) based on the American Head and
Neck Society TNM staging of head and neck cancer.9 We
present numbers and percentages overall and for different
diagnostic groups.
Results
Recruitment
We started recruiting inApril 2011 and closed to recruitment
at the end of December 2014. We opened the study in a few
centres to ensure the protocol was running smoothly before
rolling it out elsewhere. The study was open in 78UK centres
(two centres did not enrol any participants). We enrolled
5511 people into the study.
Baseline response rates
At baseline, we have received 5474 (99%) data capture forms,
4099 (74%) health and lifestyle questionnaires, 4115 (75%)
quality of life questionnaires and 3470 (63%) sexual history
questionnaires. We have obtained 4986 saliva samples
(90%), 4676 blood samples (85%) and 2301 tissue samples
(42%). Twenty-three people withdrew from completing
baseline questionnaires.
Follow-up response rates
Todate, 827 people enrolled by 24 July 2015 have died and 74
have withdrawn from the study. We have 4-month data
capture forms for 5232 (95%) and 4-month questionnaires
from 3357 (63%) participants and 12-month data capture
forms for 3906 (86%) and 12-month questionnaires from
2353 (57%) participants. These follow-up response percent-
ages are the number received against the number for which
we are expecting forms, that is those who provided baseline
data and remain in the study. They do not include
participants who have not yet reached, or died before, the
relevant 12-month window.
Recruitment and response rate by centres
Centres varied in size and joined the study at different times.
The mean number of people recruited per centre was 40
(range from 0 to >300). Similarly, there were large variations
in response rates by centres. Percentage recruitment to the
study varied from less than 20% to greater than 90% of those
eligible, response rate to the health and lifestyle question-
naire varied from less than 30% to greater than 90% and the
percentage of participants providing a blood sample varied
from less than 50% to greater than 90%.These differences are
shown in Fig. 1.
Fig. 1. Variation in recruitment and response rates by centres in
head and neck 5000. These box plots show the median and
interquartile ranges of recruitment and response rate across the
participating study centres with outliers indicated by whiskers. The
percentage consented refers to the number of eligible people who
consented to join the study whereas the other response rates refer to
the percentage of those recruited who returned a questionnaire.
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Characteristics of participants
The percentage of people enrolled in the studywas 5511 from
11 158 people who were identified as potentially eligible
(49%). The mean age of the people recruited was 61 years,
and the range was 18–96 years. The percentage of female
participants was 27%. The most common cancers were
oropharyngeal (37%), oral (26%) and laryngeal (21%). The
number and percentage of people with different diagnoses
and stage of disease is summarised inTable 1. The number of
people with complete data (defined as valid diagnosis, stage,
blood sample and baseline health and lifestyle questionnaire)
was 3336 of the 5511 (61%). The number of people with
complete data to date is shown in Fig. 2.
Discussion
We have successfully recruited 5511 people with head and
neck cancer from across the UK. We recruited people before
treatment started and obtained wide-ranging consent,
clinical information, self-reported socio-demographic, life-
style and quality of life data and biological samples.
We took time to build a clinical consensus and opened to
recruitment gradually. This delayed recruitment but meant
we encountered few local problems. One clinician initially
refused to allow people under his care to complete the sexual
behaviour questionnaire. The response rates to this ques-
tionnaire are slightly lower, but we have had no complaints
about these questions.
We recruited fewer people with salivary, thyroid and
laryngeal cancers than we expected. The lower number of
people with salivary tumours may reflect the coding of some
minor salivary gland cancers as oral cancer. The lower
number of people with thyroid cancers reflects the fact that
many are not treated by the head and neck multidisciplinary
team. The lower number of laryngeal cancers may reflect the
case mix in the study centres.
Table 1. Disease category and stage of disease in people recruited to head and neck 5000
Category Diagnosis
Grouped staging
TotalI II III IV
Upper aerodigestive tract Oropharynx 101 189 274 1317 1881
5.4% 10.1% 14.6% 70.0%
Oral cavity 427 300 101 467 1295
33.0% 23.2% 7.8% 36.1%
Larynx 435 276 174 186 1071
40.6% 25.8% 16.3% 17.4%
Hypopharynx 10 33 35 150 228
4.4% 14.5% 15.4% 65.8%
Nasopharynx 11 32 43 42 128
8.6% 25.0% 33.6% 32.8%
Sinuses 3 2 7 43 55
5.5% 3.6% 12.7% 78.2%
Nasal cavity 12 15 6 16 49
24.5% 30.6% 12.2% 32.7%
Other Thyroid 119 31 73 18 241
49.4% 12.9% 30.1% 7.5%
Salivary glands 33 21 22 55 131
25.2% 16.0% 16.8% 42.0%
Total 1151 899 735 2294 5079
22.7% 17.7% 14.5% 45.2%
The categories comprised the following ICD codes:
Oropharynx = C01, C05 and C09 (including all subcategories) and C10.0 2, C10.3, C10.8 and C10.9.
Oral cavity = C00, C02, C03,C04, C05 and C06 (including all subcategories except C06.9).
Larynx = C10.1, C32 (including all subcategories).
Hypopharynx = C12 and C13 (including all subcategories).
Nasopharynx = C11 (including all subcategories).
Sinuses = C31 (including all subcategories).
Nasal cavity = C30 (including all subcategories).
Thyroid = C73.
Salivary glands = C06.9, C07 and C08 (including all subcategories).
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Overall, around 49% of eligible people consented to join
the study and of these 61% have provided us with complete
baseline data. Therefore, we have data on around 30% of
people eligible to join the study. Our baseline response rates
were lower than we anticipated. There are several reasons for
this. We tried to obtain consent and collect data from people
in the short period between diagnosis and treatment. Clinics
were busy with limited space or time to see people. We faced
practical issues with people moving between centres for
treatment or not being discussed at the multidisciplinary
team meetings. There were also times when research nurses
were not available.
Some of the missing data may be unrelated to care or
outcome, for example, where a research nurse was
unavailable. However, much of the data will not be
missing at random and could result in bias. We may be
able reduce the impact of bias in recruitment and response
to follow-up by improving the completeness of our clinical
data and exploring the clinical characteristics of those who
did not consent to join the study by linking to national
audit data.10
Our ability to study the impact of centralisation (which
was a primary aim of our study) is limited by the low
recruitment rate, the fact that centres, although varied in
size, were self-selected and that not all centres contribut-
ing to a multidisciplinary team recruited people to the
study.
We have shown it is possible to recruit a large DNA-
backed clinical cohort in people with head andneck cancer in
the UK. This cohort is a comprehensive resource, and we
welcome collaboration.
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Fig. 2. Diagramof the number of peoplewith complete baseline data from the head andneck 5000 cohort. These data are accurate for the first
data release from the study cohort. These figures will be updated for future data releases.
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Keypoints
• Head and neck cancer is an important cause of ill
health with rapidly changing aetiology.
• Survival appears to have improved but the reasons for
this are unclear.
• Adequately powered, longitudinal studies in people
with head and neck cancer are required.
• We recruited 5511 people with head and neck cancer to
a large DNA-backed clinical cohort.
• Multicentre clinical cohort studies in head and neck
cancer are feasible in the UK.
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Dear Editor,
Concomitant chemoradiotherapy (CRT) is commonly
advocated for advanced laryngeal cancer to achieve cure
together with an allegedly organ-function preservation. This
widely applied treatment strategy has led to a paradigm shift
in the management of laryngeal cancer during the past three
decades.1 For those who are unfortunate and fail CRT,
salvage total laryngectomy (TL) may be offered as a second
line. However, post-CRT surgery encompasses intra- and
postoperative challenges, which result in increased morbid-
ity and postoperative complications.2 Moreover, with pri-
mary CRT disease-free survival rates ranging between 60%
and 80% at 5 years, the number of patients who need to be
salvaged is considerably high.3 In addition, patients, who
were cured with laryngeal organ preservation but have no
function preservation, retain their unserviceable larynx and
remain tracheostomy and/or gastrostomy dependent. These
patients may also benefit from TL.
Numerous studies have shown higher complication
rate for patients who undergo salvage TL. The most
significant complication in this regard is the formation of
pharyngocutaneous fistula (PCF), which delays postop-
erative recovery and function acquisition, increases
hospital stay and adversely affects patient’s quality of
life. Rarely, a salivary leak can erode into cervical or
mediastinal blood vessels causing potentially life-threa-
tening complications.4
The incidence of PCT following CRT is markedly
increased, with some estimates as high as 65%. These fistulas
tend to be more severe and of a longer duration. Previous
studies showed reduced incidence and even prevention of
PCF with the use of vascularized flaps such as the pectoralis
major flap (PMF) and free vascular flaps.5
This data first raise the questionwhether vascularized flaps
should be routinely employed in every salvage surgery or
only after careful patient selection. Second, have vascularized
flaps become the standard of care in the organ preservation
era? And if so, how does it affect the individual surgeon’s
decision-making process?
Correspondence: A. Mizrachi, MD, Head and Neck Service, Department of
Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New
York, NY 10065, USA. Tel.: 347-449-3137; Fax: 212-717-3302; e-mail:
mizracha@mskcc.org
This paper was presented at the 5th World Congress – IFHNOS and
Annual Meeting AHNS, July 26–30, 2014, New York, NY, USA.
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